Posted by Michael Wonder on 29 Jun 2022
Patient focused drug development: selecting, developing, or modifying fit for purpose clinical outcome assessments
29 June 2022 - This guidance (Guidance 3) is the third in a series of four methodological patient-focused drug development (PFDD) guidance documents that describe how stakeholders (patients, caregivers, researchers, medical product developers, and others) can collect and submit patient experience data and other relevant information from patients and caregivers to be used for medical product development and regulatory decision-making.
When finalised, Guidance 3 will represent the current thinking of CDER, CBER, and CDRH on this topic,.
